NCT03687684View on ClinicalTrials.gov

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

June 9, 2019

Study Completion Date

June 19, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

TAK-831

TAK-831 Tablets.

DRUG

Placebo

TAK-831 Matching Placebo Tablets.

Trial Locations (1)

Unknown

Clinical Research Hospital Tokyo, Shinjuku-ku

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY